BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALN-5288 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALN-5288\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07214727-693@assetmemo.bio
DTSTAMP:20261121T005724Z
DTSTART;VALUE=DATE:20300306
DTEND;VALUE=DATE:20300307
SUMMARY:ALN-5288: Phase 1 readout est. (NCT07214727)
DESCRIPTION:ALN-5288\, phase 1\, Alzheimer's Disease.\nStudy: A Study to Ev
 aluate ALN-5288 in Patients With Alzheimer's Disease\nEstimated primary co
 mpletion: 6 March 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/aln-5288#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07214727
URL:https://assetmemo.bio/drug/aln-5288#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
